Check here for the latest news and updates on various topics
- 2Threads
- 2Posts
- 0Threads
- 0Posts
Suggestions
If you have suggestions to recommendations that will help improve Meekspace please let us know here.
- 1Threads
- 0Posts
- 0Threads
- 0Posts
- 0Threads
- 0Posts
- 1Threads
- 0Posts
Support
Support forums for computers, tablets, phones, software, and apps.
- 0Threads
- 0Posts
Recent Discussions
Biosensors Market focused on drug discovery and development is projected to grow at an annualized rate of 9% during the period 2023-2035
In recent years, the use of biosensors in drug discovery has been on the rise, driven by several technological advancements and the growing demand for inexpensive and effective techniques for analyzing potential drug candidates
Roots Analysis has announced the addition of “Biosensors Market: Focus on Drug Discovery and Drug Development, 2023 - 2035” report to its list of offerings.
A number of drug developers are already using novel biosensors for various drug discovery applications to address the concerns associated with high rate of failures of drug development programs and requirement of high capital investments. As the adoption of biosensors, specifically for drug discovery, increases amongst innovators in the pharma and biopharma industry, lucrative opportunities are expected to be created for players engaged in the biosensors for drug discovery market.
Key Market Insights
Currently, more than 80 biosensors are being developed by various stakeholders, across the world
Majority of the biosensors (64%) engaged in this domain are optical biosensors, followed by electrochemical biosensors (25%), quartz crystal microbalance biosensors (5%) and thermal biosensors (5%). Close to 95% of the biosensors are used for lead identification step in drug discovery. Further, 15% of the biosensors claim to support all the steps in drug discovery.
Get Detailed Report: https://www.rootsanalysis.com/reports/global-biosensors-market.html
Over USD 1.2 billion invested in various domain focused initiatives, since 2018
Specifically, in 2021, industry players raised close to USD 600 billion. In addition, majority of the companies (66%) primarily received funding through venture capital rounds. Further, around 60% of the total funding instances were reported by players headquartered in the US.
In recent years, several global events related to biosensors in drug discovery were organized
Majority of the events related to biosensors in drug discovery were organized in Europe (45%). It is worth highlighting that the main agenda of these events was to discuss the development and challenges associated with the biosensors in drug discovery domain.
370+ patents related to biosensors in drug discovery have been granted / filed between 2018-2022
R&D activity related to biosensors in drug discovery is largely concentrated in North America, considering the fact that 70% of the total number of patents were filed in this region. In addition, most of the patents in this domain are granted patents (55%), followed by patent applications (44%).
North America and Europe are anticipated to capture over 70% of the market share, by 2035
In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (10%) in the long term. Further, in 2035, biosensors market for drug discovery applications for academic / research institutes is expected to capture the majority share (~60%) of the total market.
Request for Customization @ https://www.rootsanalysis.com/reports/global-biosensors-market/request-customization.html
Key Questions Answered
Who are the key players engaged in the biosensors in drug discovery market?
What is the relative competitiveness of different biosensors being developed for drug discovery applications?
What are the key agenda items being discussed in various global events / conferences related to biosensors in drug discovery?
What is the focus area of the ongoing research activity related to biosensors in drug discovery?
How is the intellectual property landscape for biosensors in drug discovery likely to evolve in the foreseen future?
What are the factors that are likely to influence the evolution of this market?
How is the current and future market opportunity likely to be distributed across key segments?
The financial opportunity within the biosensors in drug discovery market has been analyzed across the following segments:
Type of Biosensor
Optical
Electrochemical
Thermal
Others
Type of End User
Academic / Research Institutes
Industry Players
Key Geographical Regions
North America
Europe
Asia-Pacific
Latin America
MENA
Rest of the World
The report features inputs from eminent industry stakeholders, according to whom, continuous growth of biosensors market for drug discovery applications is primarily driven by the increasing adoption for such products. The report includes detailed transcripts of discussions held with the following experts:
Bill Rader (Chief Executive Officer, Efferent Labs)
Anne Marie Quinn (Chief Executive Officer, Montana Molecular)
Laurent Sabbagh (Associate Director and Head of Biology, Domain Therapeutics).
The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its biosensor product portfolio, recent developments and an informed future outlook.
Agilent Technologies
Axion Biosciences
BioNavigations
Creoptix
Cytiva
Dynamic Biosensors
Malvern Panalytical
Microvacuum
Sartorius
Tempo Bioscience
Request for Sample: https://www.rootsanalysis.com/reports/global-biosensors-market/request-sample.html
Read Our Latest Blogs:
https://www.rootsanalysis.com/blog/womens-digital-health-a-new-era-of-female-healthcare/
https://www.rootsanalysis.com/blog/sustainable-biodegradable-and-eco-friendly-packaging-a-paradigm-shift-in-healthcare-packaging/
https://www.rootsanalysis.com/blog/rising-demand-for-pharmaceutical-secondary-packaging-providers/
https://www.rootsanalysis.com/blog/single-use-technology-a-step-towards-future-transformation/
https://www.rootsanalysis.com/blog/continuous-manufacturing-a-magic-bullet-to-meet-the-demand-for-pharmaceutical-products/
Visit for More Insights: https://www.rootsanalysis.com/reports.html
Read Our Latest Press Release: https://www.rootsanalysis.com/press-releases.html
Latest Blogs On Healthcare Industry: https://www.rootsanalysis.com/blog/
Our Service Portfolio: Pipeline Tracking | Publication Analysis | Investment Analysis | Market Assessment | Competitive Profiling | Commercial Strategy and Business Development
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections
Roots Analysis has announced the addition of “Adeno-Associated Viral Vector Market, 2022-2035” report to its list of offerings.
Owing to their unique biology, simple structure and lack of disease correlation, the adeno-associated viral vectors have garnered significant interest within the medical community. In fact, various adeno-associated viral vector-based therapies have been developed for the treatment of multiple indications, including retinitis pigmentosa, cystic fibrosis and Duchenne muscular dystrophy. As a result, the demand for such vectors have increased tremendously, thereby creating lucrative opportunities for the players engaged in the adeno-associated viral vector market.
Key Market Insights
More than 550 adeno-associated viral vector-based therapies have been / are being evaluated across different stages of development for the treatment of various disorders
Close to 20% of the pipeline candidates are under clinical evaluation; majority (26%) of these candidates are being developed for the treatment of neurological disorders, followed by those being evaluated for the treatment of ophthalmic disorders (21%).
80+ industry stakeholders claim to have the required capability to manufacture adeno-associated viral vectors
The market is currently dominated by the presence of various mid-sized industry players (53%); of these 65% of the players possess in-house manufacturing capabilities, whereas 44% of players are contract manufacturers.
Get Detailed Report: https://www.rootsanalysis.com/reports/anti-agingtherapeutics-market.html
Over 30 players are involved in the development of adeno-associated viral vector platforms
More than 90% of these players offer their technologies for gene therapy, followed by those offering platforms for cell therapy (23%). It is worth mentioning that two technologies can manufacture vectors at all scales of operation, including preclinical, clinical and laboratory.
More than 155 clinical trials have been registered for the evaluation of adeno-associated viral vector-based therapies, worldwide
The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 20%, since 2010. Of the total number of trials registered, close to 25% have already been completed, while 46% of the studies are actively recruiting participants.
Partnership activity within this domain has increased at a CAGR of ~50%, between 2017 and 2021
More than 60% of the reported deals were established since 2020, with the maximum activity (~50%) being reported in 2021. Majority of the partnerships were established for product development (30%), followed by agreements inked for research and development (15%).
Over 4,370 patents have been filed / granted related to adeno-associated viral vectors, since 2017
Close to 35% of these patents were filed / granted in North America, followed by Asia-Pacific (32%). It is worth highlighting that, in addition to the industry players, various non-industry / academic players have also filed patents related to adeno-associated viral vectors; these include University of Pennsylvania, University of Florida and the Research Institute of Nationwide Children's Hospital.
More than 50 start-ups have emerged in the last 10 years in the adeno-associated viral vector domain
Close to 60% of the start-ups have been established in North America. Among these, more than 95% of the firms are based in the US. This is followed by Europe, accounting for more than 30% of the start-ups focused on adeno-associated viral vectors.
North America is anticipated to capture larger share of the adeno-associated viral vector market by 2035
The market will be primarily driven by the manufacturers developing therapies for the treatment of oncological disorders (20%). In addition, by 2035, majority market share of the adeno-associated viral vector-based therapies is anticipated to be dominated by commercial scale of operation (46%), followed by preclinical (40%) and clinical (14%).
Request for Customization @ https://www.rootsanalysis.com/reports/antiaging-therapeutics-market/request-customization.html
Key Questions Answered
Which adeno-associated viral vector-based therapy candidates are being developed across early and late stages of development? Which disease indications are targeted by such therapies?
Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of adeno-associated viral vectors?
Which type of adeno-associated viral vector related technologies are presently offered / being developed by the industry players?
Which geographies are the most active in conducting clinical trials related to adeno-associated viral vectors?
Which partnership models are commonly adopted by industry and non-industry stakeholders?
Which companies are likely to partner with adeno-associated viral vector and gene therapy product manufacturers?
What are the different initiatives recently undertaken by the start-ups engaged in the development of adeno-associated viral vectors?
Which factors are likely to influence the decision of adeno-associated viral vector therapy developers for outsourcing manufacturing operations?
How is the current and future market opportunity related to adeno-associated viral vectors likely to be distributed across key market segments?
The financial opportunity within the adeno-associated viral vector market has been analysed across the following segments:
Type of Therapy
Gene Augmentation
Immunotherapy
Other Therapies
Type of Gene Delivery Method Used
Ex vivo
In vivo
Target Therapeutic Area
Genetic Disorders
Hematological Disorders
Infectious Diseases
Metabolic Disorders
Ophthalmic Disorders
Muscle Disorders
Neurological Disorders
Others
Scale of Operation
Preclinical
Clinical
Commercial
Application Area
Gene Therapy
Cell Therapy
Vaccines
Geographical Regions
North America
Europe
Asia-Pacific
MENA
Latin America
Rest of the World
The research also includes detailed profiles of the key players (listed below) engaged in the adeno-associated viral vector market; each profile features an overview of the company, its financial information (if available), details related to its manufacturing facilities and proprietary vector manufacturing technology portfolio, and recent developments and an informed future outlook.
Abeona Therapeutics
Aldevron
Oxford BioMedica
Sanofi
WuXi AppTec
Yposkesi
The report features inputs from eminent industry stakeholders, according to whom, the anticipated increase in the demand for gene therapies, is the most prominent driver of the growth of the adeno-associated viral vector market. The report includes detailed transcripts of discussions held with following industry representatives:
Arun Srivastava (Professor of Genetics and Chief of Division of Cellular and Molecular Therapy, University of Florida)
Abhishek Chatterjee (Professor, Boston College)
Adam Lauber (Chief Financial Officer, Andelyn Biosciences)
Request for Sample: https://www.rootsanalysis.com/reports/anti-agingtherapeutics-market/request-sample.html
Read Our Latest Blogs:
https://www.rootsanalysis.com/blog/generic-drugs-rising-opportunity-forindian-pharmaceutical-players/
https://www.rootsanalysis.com/blog/social-media-in-pharmaceuticalmarketing/
https://www.rootsanalysis.com/blog/cancer-stem-cells-a-step-closer-to-thecure/
https://www.rootsanalysis.com/blog/trends-in-human-health-management-ajourney-through-time/
https://www.rootsanalysis.com/blog/genome-editing-future-potential-andethical-concerns/
Visit for More Insights: https://www.rootsanalysis.com/reports.html
Read Our Latest Press Release: https://www.rootsanalysis.com/pressreleases.html
Latest Blogs On Healthcare Industry: https://www.rootsanalysis.com/blog/ Our Service Portfolio: Pipeline Tracking | Publication Analysis | Investment Analysis | Market Assessment | Competitive Profiling | Commercial Strategy and Business Development
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
Hello All,
I am working on bringing dark mode to the site. Please be patient as I work through the process. I will post when it is ready to go.
Hello Friends,
We have refreshed the Meekspace website with a cleaner, light weight, and feature rich script. It is our goal to make the website easier to use and at the same time provide many options for our members. Please spend some time getting familiar with the new website and let us know what you think.
Trends
Trending since March 22, 2023